Abstract
Alzheimer’s disease (AD) results in the deposition of amyloid β (Aβ) peptide into amyloid fibrils and tau into neurofibrillary tangles. Regardless of whether or not these entities are a cause or consequence of the disease process, preventing their accumulation or accelerating their clearance may slow the rate of AD onset. Motoneuronotrophic factor (MNTF) is an endogenous neurotrophin that is specific for the human nervous system, and some of the observed effects of MNTF include motoneuron differentiation, maintenance, survival, and reinnervation of target muscles and organs. GM6 is a six-amino-acid component of MNTF that appears to replicate its activity spectrum. In this study, we investigated the effect of GM6 in a mouse model of AD before the development of amyloid plaques and determined how this treatment affected the accumulation of Aβ peptide and related pathologic changes (e.g., inflammation, nerve growth factor (NGF) expression, cathepsin B, and memory impairment). Application of GM6 over a 4-month period in young APP/ΔPS1 double-transgenic mice resulted in attenuation in Aβ peptide levels, reduction of inflammation and amyloid load, increased cathepsin B expression, and improved spatial orientation. In addition, treatment with GM6 increased brain NGF levels and tempered memory impairment by ∼ 50% at the highest dose. These data suggest that GM6 may modulate disease-determining pathways at an early stage to slow the histological and clinical progression of AD.
Similar content being viewed by others
Change history
23 March 2019
The name of author “William Swindell” missed the midle initial “R.”. This should be written as “William R. Swindell” as corrected above.
References
Mayeux R (2010) Clinical practice. Early Alzheimer’s disease. N Engl J Med 362:2194–2201
Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–344
Li S, Shankar GM, Selkoe DJ (2010) How do soluble oligomers of amyloid beta-protein impair hippocampal synaptic plasticity? Front Cell Neurosci 4:5
Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, Hedden T, Becker JA et al (2010) Functional alterations in memory networks in early Alzheimer’s disease. NeuroMolecular Med 12:27–43
Walsh DM, Selkoe DJ (2007) A beta oligomers - a decade of discovery. J Neurochem 101:1172–1184
Lahiri DK, Zawia NH, Greig NH, Sambamurti K, Maloney B (2008) Early-life events may trigger biochemical pathways for Alzheimer’s disease: the “LEARn” model. Biogerontology 9:375–379
Selkoe DJ (2007) Developing preventive therapies for chronic diseases: lessons learned from Alzheimer’s disease. Nutr Rev 65:S329–S343
Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73:768–775
Chau RMW, Ren F, Huang W, Jen LS (1992) Muscle neurotrophic factors specific for anterior horn motoneurons of rat spinal cord. Recent Adv Cell Mol Biol 5:89–94
Zhou MH, Wu XY, Ren F, Zhao LP, Huang WQ, Yang ZY, Ren LS (1992) Effect of 22kD, 35kD molecules from skeletal muscle extract on ant. Horn motoneuron of lumbar spine in rat. Chin Sci Bull 37:1742–1745
Zhou MH, Yu WH, Reb F (1993) Changes in MNTF and its receptor in tongue muscle post-denervation of the hypoglossal nerve. Acta Anatomica Sin 24:391–395
Wang AM, Chau RMW, Chow SP, Zhang ZY, Li ZM (1995) Effects of myogenic 22 and 35kD neurotrophic factors on axonal regeneration in free peripheral autografts into rat spinal cord. Chin J Spine Spinal Cord 5:248–252
Chau, R.M.W. 2001. Polynucleotides encoding motoneuronotrophic factors. US Patent. #6,309,877.
Chau, R.M.W. 2005. Methods and use of motoneuronotrophic factors. US Patent. #6,841,531.
Chau, R.M.W. 2007. MNTF peptides and compositions and methods of use. US patent. #7,183,373.
Yu J, Zhu H, Ko D, Kindy MS (2008) Motoneuronotrophic factor analog GM6 reduces infarct volume and behavioral deficits following transient ischemia in the mouse. Brain Res 1238:143–153
Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK et al (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159–170
Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F et al (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer’s disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18:602–617
Hook VY, Kindy M, Hook G (2008) Inhibitors of cathepsin B improve memory and reduce A beta in transgenic Alzheimer’s disease mice expressing the wild-type, but not the Swedish mutant, betasecretase AβPP site. J Biol Chem 283:7745–7753
Elvington A, Atkinson C, Zhu H, Yu J, Takahashi K, Stahl GL, Kindy MS, Tomlinson S (2012) The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol 189:4640–4647
El-Amouri SS, Zhu H, Yu J, Gage FH, Verma IM, Kindy MS (2008) Neprilysin: an enzyme candidate to treat Alzheimer’s disease. Am J Pathol 172:1342–1354
Hook V, Hook G, Kindy MS (2010) Pharmacogenetic features of inhibitors to cathepsin B that improve memory deficit and reduces beta-amyloid related to Alzheimer’s disease. Biol Chem 391:861–872
Yu J, Gattoni-Celli M, Zhu H, Bhat NR, Sambamurti K, Gattoni-Celli S, Kindy MS (2011) Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of APP transgenic mice. J Alzheimers Dis 25:295–307
Hook G, Yu J, Toneff T, Kindy M, Hook V (2014) Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer’s disease therapeutic. J Alzheimers Dis 41:129–149
Kochanek KD, Murphy SL, Xu J, Tejada-Vera B (2016) Deaths: final data for 2014. Natl Vital Stat Rep 65:1–122
Karran E, De Strooper B (2016) The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem 139:237–252
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8:595–608
Holtzman DM, Mandelkow E, Selkoe DJ (2012) Alzheimer disease in 2020. Cold Spring Harb Perspect Med 2(11). https://doi.org/10.1101/cshperspect.a011585
Hung SY, Fu WM (2017) Drug candidates in clinical trials for Alzheimer’s disease. J Biomed Sci 24:47
Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A et al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141:1917–1933
Selkoe DJ (2013) The therapeutics of Alzheimer’s disease: where we stand and where we are heading. Ann Neurol 74:328–336
Godyn J, Jonczyk J, Panek D, Malawska B (2016) Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep 68:127–138
LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-[beta] in Alzheimer’s disease. Nat Rev Neurosci 8:499–509
Akiyama H, Arai T, Kondo H, Tanno E, Haga C, Ikeda K (2000) Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord 14(Suppl 1):S47–S53
Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12:383–388
Garcia ML, Cleveland DW (2001) Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr Opin Cell Biol 13:41–48
Zhou MH, Wu X, Chen S (1997) Distribution of MNTF1 in spinal cord and limb muscles of mice with motoneuron disease. Acta Acad Med Sin 19:171–178
Di X, Huang W (1997) Localization and morphometric study on motoneuronotrophic factor 1 and its receptor in developing chorionic villi of human placenta. Acta Anatomica Sin 29:86–89
Di X, Huang WQ, Sun L (1997) Immunohistochemical localization of c-fos p53 protein & MNTF1 receptor in early human placental villi. Acta Anatomica Sin 28:404–406
Kindy M, Lupinacci P, Chau R, Shum T, Ko D (2017) A phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with amyotrophic lateral sclerosis (ALS protocol GALS-001) and a single compassionate patient treatment (protocol GALS-C). F1000 Res 6:230
Valko KL, Kindy M, Evans J, Ko D (2018) In vitro biomimetic HPLC and in vivo characterisation of GM6, an endogenous regulator peptide drug candidate for amyotrophic lateral sclerosis. ADMET & DMPK 6:162–175
Yu J, Zhu H, Perry S, Taheri S, Kindy MS (2017) Daily supplementation with GrandFusion® improves memory and learning in aged rats. Aging 9:1041–1054
Valko KL, Ivanova-Berndt G, Beswick P, Kindy M, Ko D (2018) Application of biomimetic HPLC to estimate lipophilicity, protein and phospholipid binding of potential peptide therapeutics. ADMET & DMPK 6:153–161
Imbimbo BP (2009) An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer’s disease. Expert Opin Investig Drugs 18:1147–1168
Olsen I, Singhrao SK (2016) Inflammasome involvement in Alzheimer’s disease. J Alzheimers Dis 54:45–53
Swindell WR, Bojanowski K, Kindy MS, Chau RMW, Ko D (2018) GM604 regulates developmental neurogenesis pathways and the expression of genes associated with amyotrophic lateral sclerosis. Transl Neurodegener 7:30
Acknowledgements
We would like to thank Winston Ko for his support of the studies.
Funding
This work was partially supported by grants from the National Institutes of Health (R01 ES016774-01, R21AG043718, 1P20GM109091, 2P20GM103444, and 5P30GM103342), VA Merit Award (1I01RX001450-01A1), a grant from the National Science Foundation (IIP-0903795), and an AHA SFRN (15SFDRN25710468) grant (M.S.K.). Dr. Kindy is a Senior Research Career Scientist in the VA.
Author information
Authors and Affiliations
Contributions
Conceived and designed the experiments: JY, ST, CK, DK, and MSK. Performed the experiments: JY, HZ, ST, WM, and MSK. Performed data analysis: CK and MSK. Contributed reagents/materials/analysis tools: DK. Wrote and contributed to the writing of the manuscript: CK, DK, and MSK. All authors discussed the results and edited the manuscript.
Corresponding author
Ethics declarations
This research was approved by the IACUC of the University of South Florida, following the guidelines for the Care and Use of Laboratory Animals.
Competing Interest
Dorothy Ko is an employee of Genervon and has interest in the company.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yu, J., Zhu, H., Taheri, S. et al. GM6 Attenuates Alzheimer’s Disease Pathology in APP Mice. Mol Neurobiol 56, 6386–6396 (2019). https://doi.org/10.1007/s12035-019-1517-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-019-1517-2